Horizon Pharma aborts key Actimmune trial; shares plunge

(Reuters) – Horizon Pharma Plc’s shares tumbled 18 percent after the company ended a late-stage trial that was testing its drug, Actimmune, as a treatment for a rare neuromuscular disorder that has no approved medicines. Actimmune failed to demonstrate a statistically significant benefit over a placebo in patients with Friedreich’s ataxia (FA) on a scale used to measure progression of the disease, the company said. The drug is already approved by the U.S. Food and Drug Administration for use in two rare, genetic conditions – chronic granulomatous disease and severe, malignant osteopetrosis.
Go to Source